Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Frontiers in Oncology|November 7, 2014
Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancerZaker Rana, Robyn A Cyr, Leonard N Chen, et al.
Frontiers in Oncology|April 18, 2022
Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate CancerMichael C Repka, Michael Creswell, Jonathan W Lischalk, et al.
Radiation Oncology (London, England)|February 12, 2014
Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancerOnita Bhattasali, Leonard N Chen, Jennifer Woo, et al.
Radiation Oncology (London, England)|March 5, 2013
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safetyMarie K Gurka, Sean P Collins, Rebecca Slack, et al.
Frontiers in Oncology|August 24, 2013
Five fraction image-guided radiosurgery for primary and recurrent meningiomasEric Karl Oermann, Rahul Bhandari, Viola J Chen, et al.
Frontiers in Oncology|June 7, 2014
Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancerJennifer A Woo, Leonard N Chen, Aditi Bhagat, et al.
Frontiers in Oncology|February 23, 2017
Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year ToxicityIma Paydar, Abigail Pepin, Robyn A Cyr, et al.
Radiation Oncology (London, England)|July 25, 2014
Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancerW Tristram Arscott, Leonard N Chen, Nathan Wilson, et al.
Radiation Oncology (London, England)|June 27, 2014
Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancerLeonard N Chen, Simeng Suy, Hongkun Wang, et al.
Radiation Oncology (London, England)|February 2, 2013
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancerAndrew W Ju, Hongkun Wang, Eric K Oermann, et al.
Pageof 8